Ivermectin dose calculator, with optional fenbendazole
A dose without a source is a dose in the dark.
In the tables that circulate, nobody says which article the number came from, the presentation is not the one sold in Brazil and there is no schedule of lab tests. The calculator does the opposite: dose by weight, the source next to every number and the monitoring plan, in a PDF that the health professional takes to the medical record and the patient takes to the appointment, always with professional follow-up.
Launch: US$ 15, one-time payment, lifetime access. After the launch, US$ 60.
Payment through Stripe. No subscription, no card stored on this site.
The problem
A number without an origin serves neither the health professional nor the patient.
In drug repurposing, dose tables without a source circulate, along with schedules copied from forums and two drugs with different regulatory status treated as if they were one. The risk is not only the wrong dose: it is not knowing where it came from.
Doses without provenance
Ready-made tables say how much to take, but not which article or trial the number came from, nor whether it was tested in people or only in animal models.
Two drugs, two statuses
Ivermectin is used outside its registered indication (off-label). Fenbendazole has no registration for human use with ANVISA and exists only in veterinary presentations in Brazil. Mixing the two hides that difference.
Conversion error
The 222 mg sachet from the foreign literature contains 1 gram of granules at 22.2% and is not sold in Brazil. Confusing 1 g with 222 mg gets the dose wrong by 4.5 times.
No monitoring plan
Liver injury from self-medication with fenbendazole has been described in about 7 days (PMID 38706451). Whoever starts without a baseline test and without a collection schedule finds out late.
None of this replaces the health professional. The document exists to move the conversation with them onto the ground of sources.
How it works
Four steps. Every choice with the source next to it.
The calculator is a step by step. Each step shows only its own choices, with the provenance right below the selector, and the last one gathers everything before generating the document.
Patient details
Name (goes only to the document's identification), weight from 30 to 200 kg, age from 18 to 100 years, established liver disease and the switch that includes fenbendazole.
Ivermectin parameters
Target dose among 5 levels with provenance, from 0.4 to 2.0 mg/kg, and the weekly schedule: 3 consecutive days, as in the registered trials, or daily. The start is gradual: 0.2 and 0.3 mg/kg before the target dose.
Fenbendazole parametersoptional
222 or 444 mg per day, the same for all weight ranges, converted to the 100 mg/mL suspension sold in Brazil and compared with the 500 mg double-scored tablet.
Review and document
Summary of the choices, consolidated alerts, doses per phase and the button that generates the PDF on the server. No patient data is stored.
Outside the weight and age ranges nothing is generated: outside them there is no bibliographic support.
The document
A PDF that explains itself.
Eleven sections with fenbendazole, nine without. From the header to the legal notice, the patient and the health professional read the same document, with the same sources.
The sections, in the order they come out
- 1.Identification
- 2.Dose calculation summary - Ivermectin
- 3.Protocol 1 - Combined (Ivermectin + Fenbendazole)fenbendazole only
- 4.Protocol 2 - Ivermectin alone (monotherapy)
- 5.Comparison table - Protocol 1 vs. Protocol 2fenbendazole only
- 6.Administration rules
- 7.Consideration by age range
- 8.Monitoring and safety
- 9.Glossary of acronyms and terms
- 10.Scientific references
- 11.Legal notice
Without fenbendazole, its sections are removed and the numbering closes from 1 to 9, with no gap. The header becomes "Ivermectin - Drug Repurposing".
Provenance printed next to every dose
Which article, trial registration or practice convention the number comes from. Where there is no source, it says so.
Weekly calendar and administration rules
The days of each drug in the week, taking with food and the presentations sold in Brazil.
Monitoring with 5 tests and suspension criteria
Baseline, week 4, week 6 and then every 8 weeks for liver function; stopping thresholds in plain text.
Glossary with 33 terms and 7 references with links
Acronyms explained inside the document and articles indexed in PubMed, with a clickable PMID.
A4, selectable text, clickable PubMed links, generated on the server from the same choices as the review. The screen and the document use the same calculation.
Pages of the sample document
Generated for a fictional patient, 72 kg and 58 years old, with fenbendazole. Selectable text and clickable links in the real PDF.
Safety and transparency
What the calculator does not do is as important as what it does.
It does not prescribe, does not adjust the dose on its own and does not hide a gap. Every limit is stated in text, on screen and in the document.
3 safety alerts
Triggered at the step where the choice is made and repeated in the document, right after the identification:
- Declared liver disease with a dose above the range with preclinical support
- Fenbendazole at 444 mg/day - doubled weekly exposure
- Daily schedule selected - weekly exposure more than double that of the trials
No alert changes the dose on its own: the professional decides, the calculator informs.
5 monitored tests
The document's monitoring table, with frequency and action criterion for each row:
- AST / ALT / GGT
- Total bilirubin
- Complete blood count
- Serum calcium
- 25-OH Vitamin D3
Liver schedule: baseline, week 4, week 6 and then every 8 weeks. Above 3 times the upper limit of normal, immediate suspension.
Transparency note
Where there is no source, the document says so. The liver schedule is safety reasoning around the first escalation of ivermectin, not a transcription of a specific source, and it is declared as such in the PDF. No dose is estimated or inferred.
Consideration by age range
From 18 to 60 years, from 61 to 74 and from 75 on: each range gets its own note in the document, with the liver care and the limitation of data in the very elderly written out in full.
Provenance of 0.4 mg/kg, the default target dose
Human equivalent of the median effective dose in animal tumor models (5 mg/kg) - Juarez 2018, PMID 29531862. There is preclinical evidence of an antitumor mechanism (Melotti 2014, PMID 25170868; Hashimoto 2009, PMID 19920927); the effective dose in patients has not been established in a clinical trial.
Fixed notice of the calculator, reproduced in the document
Who it is for
For those who conduct the treatment and for those who follow it closely.
Anyone can purchase access. What changes is the use: the professional decides, the patient talks to the one who decides.
For health professionals
Health professionals who need a document with sources for the medical record and for the conversation with the patient.
- Five target-dose levels with provenance (Juarez 2018, Guzzo 2002), instead of a percentage scale of the maximum tolerated dose, which does not exist in this context.
- Two published weekly schedules: 3 consecutive days, as in trials NCT05318469 and NCT07487805, or daily, with the difference in weekly exposure made explicit.
- Conversion to 6 mg and 3 mg human tablets and to the Brazilian presentations of fenbendazole: 100 mg/mL suspension and 500 mg double-scored tablet.
- Monitoring table, suspension criteria and alerts in the same text the document prints: what you read on screen is what the patient takes with them.
For patients and caregivers
Those who follow the treatment closely and want to understand, with sources, what is being discussed with the health professional.
- Use it with guidance from a health professional: the document does not prescribe, does not replace the appointment and does not decide anything on its own.
- Take the document to the health professional who follows you: it shows where each number comes from, which tests to follow and when to stop.
- Glossary with 33 terms to understand acronyms such as ULN, AST and PMID without leaving the PDF.
- Your data is not kept: name, weight and age exist only while the document is generated.
In numbers
Everything here can be checked in the document.
7
references indexed in PubMed
11
sections in the document
33
terms in the glossary
5
dose levels with provenance
2 weekly schedules · 3 safety alerts · 5 monitored tests · weight from 30 to 200 kg · age from 18 to 100 years
- No patient data is stored
- PDF generated on the server, with selectable text and clickable links
- Sources: PubMed, trial registrations and regulatory agencies
Launch offer
US$ 15 today. Lifetime access.
While the launch lasts, lifetime access costs US$ 15 in a one-time payment. When the launch ends, the same access goes to US$ 60.
US$ 15
US$ 60final price after the launch
one-time payment · lifetime access
- Lifetime access to the calculator, with no renewal and no subscription
- Complete PDF document: 11 sections, 7 references, glossary and legal notice
- Optional fenbendazole, with the presentations sold in Brazil
- 3 safety alerts and monitoring table with 5 tests
- Email support
Payment processed by Stripe, by card, in US dollars.
Already signed up and did not complete the payment? Generate a new link
Why US$ 15?
The launch is meant to put the document in the hands of those who need it now and to listen to those who use it. That is why the entry price is a fraction of the final price.
There is no announced date for the end of the launch. When it ends, the price changes here and at checkout, and whoever already secured access pays no difference.
FAQ
Frequently asked questions
From professionals and from patients. If yours is not here, write to faq@ivercalc.com.
Get in while it is the launch.
US$ 15, one-time payment, lifetime access. After the launch, US$ 60.
Educational document. It does not constitute a prescription. Ivermectin in off-label use; fenbendazole with no registration for human use with ANVISA, in Brazil.